Abstract:Background: Aryl hydrocarbon receptor nuclear translocator-like 2 (ARNTL2) belongs to the b HLH- PAS domain transcription factor family and is one of the key clock genes that control the circadian rhythm. ARNTL2 plays an important role in human biological functions. However, its role in various tumors, especially in the tumor immune microenvironment (TIME) and immunotherapy, remains unclear. Methods: We integrated data from cancer patients from multiple databases, including the Cancer Genome Atlas, Cancer Cell Lineage Encyclopedia, Genotype Tissue Expression, Human Protein Atlas, cBioPortal, TIMER, and ImmuCellAI, with data from a large clinical study, three immunotherapy cohorts, and in vitro experiments to investigate the involvement of ARNTL2 expression in cancer prognosis and immune response. Results: ARNTL2 displayed abnormal expression within most malignant tumors, and is significantly associated with poorer survival and pathologic staging. Through gene-set enrichment analysis (GSEA) and gene-set variation analysis (GSVA), we found that ARNTL2 not only regulates cell cycle-related functions to promote cell proliferation but also regulates autoimmunity-related functions of the innate and adaptive immune systems, and other immune-related signaling pathways. In addition, ARNTL2 overexpression contributes to an immunosuppressive tumor microenvironment that plays a key role in immunosuppression-related features, such as the expression of immunosuppression-related genes and pathways and the number of immunosuppressive-infiltrating cells, including regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs). The group of patients with low ARNTL2 expression who received immune checkpoint inhibitors (ICI) therapy had better response rates and longer survival when compared to those with high ARNTL2 expression. Conclusion: The findings of this study suggest that ARNTL2 is a potential human oncogene that plays an important role in tumorigenesis and cancer immunity. Elevated ARNTL2 expression indicates an immunosuppressive tumor microenvironment. Targeting ARNTL2 in combination with ICI therapy could bring more significant therapeutic benefits to patients with cancer. Our study sheds light on the remarkable potential of ARNTL2 in tumor immunity and provides a novel perspective for anti-tumor strategies.

Overexpression of ARNT2 is Associated with Decreased Cell Proliferation and Better Prognosis in Gastric Cancer

Downregulation of ARNT2 Promotes Tumor Growth and Predicts Poor Prognosis in Human Hepatocellular Carcinoma

ARNT2 is Downregulated and Serves As a Potential Tumor Suppressor Gene in Non-Small Cell Lung Cancer

Upregulation of ARNTL2 is Associated with Poor Survival and Immune Infiltration in Clear Cell Renal Cell Carcinoma

Aryl Hydrocarbon Receptor Nuclear Translocator is Associated with Tumor Growth and Progression of Hepatocellular Carcinoma

Upregulation of ARNTL2 Predicts Poor Survival for Clear Cell Renal Cell Carcinoma and Explores Its Associations with PD-L1 and Immune Infiltration

ARNTL2 is an Indicator of Poor Prognosis, Promotes Epithelial-to-mesenchymal Transition and Inhibits Ferroptosis in Lung Adenocarcinoma

The circadian rhythm key gene ARNTL2: a novel prognostic biomarker for immunosuppressive tumor microenvironment identification and immunotherapy outcome prediction in human cancers

Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients with Gastric Cancer.

Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma

Overexpression of TC2N is Associated with Poor Prognosis in Gastric Cancer.

Targeting the ARNTL2 Gene as a Potential Strategy for Lung Adenocarcinoma

ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma

IDDF2019-ABS-0263 Androgen Receptor Promotes Gastric Carcinogenesis Via Upregulating the Expression of Cell Cycle-Related Kinase

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Upregulation of OTX2-AS1 is Associated With Immune Infiltration and Predicts Prognosis of Gastric Cancer

AGR2 is associated with gastric cancer progression and poor survival.

Androgen Receptor Promotes Gastric Carcinogenesis Via Upregulating Cell Cycle-Related Kinase Expression.

ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells

Correlation Between Trop2 and Amphiregulin Coexpression and Overall Survival in Gastric Cancer.

Up-regulation of Ago2 expression in gastric carcinoma